INTRODUCTION AND OBJECTIVES: Recognition of the urothelium as a new sensory structure and its potential role in mediating bladder dysfunction has led to great interest in identifying its pathological mediators. Oxidative stress is a fundamental pathological mediator and ROS-generating enzyme NADPH-oxidase (Nox) has particular importance as it is the only enzyme in the body that produces ROS as its sole function and can serve as specific ROScontrolling target without compromising normal biochemical oxidation. Our recent study has identified such system in bladder urothelium (1). To explore molecular mechanisms of superoxide production and the pathological significance of Nox-associated oxidative stress, we examined the effect of Nox-subtype deletion and several pathologically important inflammatory factors on Nox-derived superoxide production in bladder urothelial tissue.
METHODS: Wild type C57BL/6J mice, Nox-1 and Nox-2 knockout mice and their wild type littermates were used in compliance with the regulations. Bladder mucosa and full-thickness bladder tissue were isolated under microscopic guidance. NADPHdependent superoxide production in live tissue was determined by lucigenin-enhanced chemiluminescence.
RESULTS: Nox-1 deletion reduced the superoxide production to 64.7AE7.5% of wild type littermate control (meanAESEM; n[6, p<0.01), showing Nox-1 contribution to endogenous superoxide production. Nox-2 deletion reduced the superoxide level to 78.0AE 5.8 % of the control (n[9, p<0.01), demonstrating Nox-2 contribution. Angiotensin II (1µM), a trophic factor and vessel constrictor which is endogenously released and involved in bladder outflow obstruction and hypertrophy, increased the superoxide production from 85.6AE6.3 to 138AE11.7 RLU/mg tissue (n[16, p<0.01). TRPV4-specific activator GSK1016790A (1µM), which participates in sensory dysfunction and bladder pain, enhanced the superoxide production in mucosa-attached bladder strips from 89.7AE5.5 to 118.8 AE5.6 RLU/mg tissue (n[10, p<0.01). Endothelin-1 (1µM), an inflammatory factor endogenously released in tissue ischemia, also augmented the superoxide production in bladder mucosa from 44.5AE7.6 to 90.2AE17.9 RLU/mg tissue (n[10, p<0.05).
CONCLUSIONS: These new data show that Nox-1 and Nox-2 subtypes contribute to endogenous superoxide production in bladder urothelium. The results also provide the first evidence that inflammatory factors angiotensin II, GSK1016790A and endothelin-1 can upregulate the Nox-derived superoxide production in bladder mucosa and demonstrate the pathological significance of Noxassociated oxidative stress. 
PD14-12 NICOTINIC RECEPTORS ON NERVE TERMINALS INDUCE
INTRODUCTION AND OBJECTIVES: Carbachol, a mixed muscarinic and nicotinic agonist similar to acetylcholine, is often used for in-vitro bladder contraction with the implicit assumption that it causes contraction by only activating bladder smooth muscle muscarinic receptors. We sought to determine whether nicotinic receptors may also be involved in canine detrusor muscle contractions in-vitro.
METHODS: Mucosa denuded female canine bladder muscle strips from sham operated animals were used from a larger study of nerve transfer for bladder reinnervation. Strips were fixed between force transducers and positioners and suspended in Tyrode's solution bubbled with 95% O2/5% CO2 at 37 C. After stretching to a length of optimal force production, maximal responses to 120 mM KCl were determined then antagonists were added for 20 minutes before inducing contraction with the nicotinic agonists epibatidine and nicotine itself.
RESULTS: Epibatidine induced contractions that were 40% of the maximal response to 120 mM KCl whereas nicotine only induced contractions that were 20% of KCl. The muscarinic receptor antagonist atropine (10 uM) completely blocked 10 mM epibatidine or 1 mM nicotine induced contractions but desensitization of purinergic receptors with 10 uM a,b methylene ATP did not. Blocking sodium channels with 1 uM tetrodotoxin (TTX) had no statistically significant inhibitory effect on epibatidine or nicotine induced contractions. Desensitizing nicotinic receptors by exposure to nicotine blocked contractile responses to epibatidine and vice versa. The skeletal muscle neuromuscular junction nicotinic receptor antagonist atracurium besylate (5 uM) blocked both epibatidine and nicotine induced contractions. Epibatidine contractions were also completely blocked by another skeletal muscle neuromuscular junction nicotinic receptor antagonist tubocurarine (1 uM) or the ganglionic nicotinic antagonists hexamethonium (100 uM) or mecamylamine (10uM).
CONCLUSIONS: Because of atropine blockade but not blockade by a,b methylene ATP desensitization, the nicotinic agonists induce bladder contractions indirectly by releasing acetylcholine from intramural nerve terminals. Because TTX was ineffective, these nicotinic receptors do not need to induce action potentials and thus are likely located near the neuromuscular junction. The nature of these nicotinic receptors appears to be somewhat unusual in that they can be blocked by antagonists thought to be selective for skeletal muscle neuromuscular junction nicotinic receptors (atracurium and tubocurarine) as well as ganglionic nicotinic receptors (hexamethonium and mecamylamine). FSH is a pituitary hormone that regulates testosterone and is elevated with LHRH-a therapy. Some data suggest FSH may mediate the potential effects of ADT on MACE, though population-level data assessing this are lacking. We examined the effect of serum FSH on all-cause mortality (ACM) and MACE in men treated with ADT for PC.
